Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
The 17beta-hydroxysteroid dehydrogenases (17beta-HSDs) are involved in the last step of the biosynthesis of sex steroids from cholesterol. This family of steroidogenic enzymes constitutes an interesting target in the control of the concentration of estrogens and androgens. Among the isoforms of 17beta-HSD, type II preferentially catalyzes the oxidation of estradiol (E(2)), testosterone (T), dihydrotestosterone (DHT), and 20alpha-dihydroprogesterone (20alpha-DHP). Based on structure-activity relationship studies, we have developed steroidal spirolactones as inhibitors of type II 17beta-HSD using different steroid nuclei: a C18-steroid (lactones 1 and 10), an antiestrogenic nucleus (lactone 2), and a C19-steroid (lactone 28). We know these inhibitors are selective for type II 17beta-HSD as no or only weak inhibition was observed for types I and III. They also have no proliferative (androgenic) activity on androgen sensitive (AR(+)) Shionogi cells whereas their proliferative (estrogenic) activity on estrogen sensitive (ER(+)) ZR-75-1 cells depends on the nature of the steroid nucleus. Lactones 1 and 10 are weak estrogens, while lactones 2 and 28 do not exert estrogenic activity, in fact lactone 2 is an antiestrogen. Lactones 1, 2, 10 and 28 were also tested in an identical assay with a series of enzyme substrates, C19-steroid diols, and known inhibitors, for the oxidation of testosterone and estradiol into androstenedione and estrone, respectively. From this comparative study, the best inhibitors of type II 17beta-HSD (oxidase activity) were identified, but none of them were clearly more potent than the hydroxylated (reduced) forms of enzyme substrates, E2, T, and DHT. Such inhibitors remain, however, useful tools to, (1) further elucidate the role of type II 17beta-HSD, and (2) regulate the level of active estrogens, androgens and progesterone.
Poirier
D
D
Medicinal Chemistry Division, Oncology and Molecular Endocrinology Research Center, Laval University Medical Centre (CHUL), 2705 Laurier Boulevard, G1V 4G2, Quebec, Canada. donald.poirier@crchul.ulaval.ca
Bydal
P
P
Tremblay
M R
MR
Sam
K M
KM
Luu-The
V
V
D015067:17-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors* / Q000235:genetics; D002460:Cell Line; D013196:Dihydrotestosterone / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D004958:Estradiol / Q000737:chemistry / Q000378:metabolism; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000235:genetics; D007668:Kidney; D009249:NADP / Q000494:pharmacology; D010920:Placenta / Q000201:enzymology; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D013148:Spironolactone / Q000737:chemistry / Q000494:pharmacology; D013256:Steroids / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000378:metabolism; D014162:Transfection
D004791:Enzyme Inhibitors; D007527:Isoenzymes; D011994:Recombinant Proteins; D013256:Steroids; D013196:Dihydrotestosterone; D013148:Spironolactone; D013739:Testosterone; D004958:Estradiol; D009249:NADP; D015067:17-Hydroxysteroid Dehydrogenases